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Abstract: Data from two open-label trials (PRIOR and CURRENT) of women with 
postmenopausal osteoporosis or osteopenia were evaluated to assess whether monthly oral 
and quarterly intravenous (IV) ibandronate dosing improved self-reported gastrointestinal (GI) 
tolerability for patients who had previously experienced GI irritation with bisphosphonate (BP) 
use. In PRIOR, women who had discontinued daily or weekly BP treatment due to GI intolerance 
received monthly oral or quarterly IV ibandronate for 12 months. The CURRENT subanalysis 
included women receiving weekly BP treatment who switched to monthly oral ibandronate for 
six months. GI symptom severity and frequency were assessed using the Osteoporosis Patient 
Satisfaction Questionnaire™. In PRIOR, mean GI tolerability scores increased significantly at 
month 1 from screening for both treatment groups (oral: 79.3 versus 54.1; IV: 84.4 versus 51.0; 
p  0.001 for both). Most patients reported improvement in GI symptom severity and frequency 
from baseline at all post-screening assessments (90% at Month 10). In the CURRENT 
subanalysis 60% of patients reported improvements in heartburn or acid reflux and 70% 
indicated improvement in other stomach upset at month 6. Postmenopausal women with GI 
irritability with daily or weekly BPs experienced improvement in symptoms with extended 
dosing monthly or quarterly ibandronate compared with baseline.
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Introduction
Declining postmenopausal estrogen levels lead to an increase in bone turnover and a 
decrease in bone mass. The resulting osteoporosis is a cause of substantial morbidity, 
reduction in quality of life, and increased mortality.1,2 Bisphosphonates (BPs), which 
are the treatment of choice, have proven efficacy in terms of bone turnover marker 
reduction, bone mineral density increase, and fracture risk reduction.3–6 However, their 
effectiveness in clinical practice is often compromised by poor adherence to dosing 
instructions and poor persistence with treatment.7
Treatment discontinuation is associated with increased risk of fractures8–10 and has 
been attributed to several causes, including patients’ experience of gastrointestinal (GI) 
side effects, such as esophageal irritation and ulceration, associated with oral BPs.11–13 
The GI irritation observed with oral BPs is a result of direct contact between the drug 
and gastric mucosa.14 BPs act as topical irritants on the gastric mucosa, leading to 
mucosal necrosis.15 The effects can be minimized by following the dosing instruc-
tions, which are intended to minimize direct contact.16 Less frequent administration 
may also help by allowing time for the gastric mucosa to recover between doses. In a 
database study, the risk of severe GI events was significantly lower for patients treated Clinical Interventions in Aging 2009:4 358
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with ibandronate than with weekly BPs.17 However, this study 
did not assess milder GI symptoms. The rate of GI adverse 
events was similar to placebo with all BPs in a number of 
randomized clinical trials (RCTs),4,5,18–21 in contrast to reports 
supporting a link between BP treatment and GI symptoms 
from routine clinical practice.12,22 This difference may reflect 
the generally healthier populations typically included in 
clinical trials compared with those treated in routine clinical 
practice, or factors such as better compliance with dosing 
instructions in clinical trials or under-reporting of adverse 
events in clinical trials.
Ibandronate, a nitrogen-containing BP indicated for 
prevention and treatment of postmenopausal osteoporosis, 
is available as monthly oral and quarterly intravenous (IV) 
formulations,23,24 thus allowing for the evaluation of GI symp-
toms with extended BP dosing regimens. The purpose of this 
investigation was to consider data from two clinical trials of 
ibandronate in order to assess whether extended BP dosing 
was associated with improved GI tolerability for patients 
who indicated previous GI irritation with daily or weekly 
BP use using self-reported questionnaires with questions 
specifically addressing GI symptoms.
Materials and methods
study design
The frequency and severity of GI symptoms with 
ibandronate were assessed using questionnaires in two open-
label, multicenter clinical trials, PRIOR25 and CURRENT.26 
PRIOR was a 12-month study that enrolled women who 
had discontinued daily or weekly BP treatment due to GI 
symptoms at least three months previously. The participants 
chose to receive either the 150 mg monthly oral or 3 mg 
quarterly IV ibandronate dose. CURRENT was a large, 
prospective, open-label, multicenter, six-month study 
designed to identify the level of patient satisfaction with 
once-monthly BP therapy in patients previously treated 
with weekly BPs, using the validated Osteoporosis Patient 
Satisfaction Questionnaire (OPSAT-Q)™.27 In PRIOR, all 
patients were required to take supplemental calcium and 
vitamin D for the full duration of the study and the sponsor 
provided patients with a combination dietary supplement 
containing vitamin D 200 IU and elemental calcium 
500 mg. In CURRENT, all patients were instructed to take 
supplemental calcium and vitamin D for the full duration 
of the study. In both studies, patients were instructed to 
take calcium and vitamin D in divided daily doses with 
a meal. Under no circumstances was the patient to take 
calcium, vitamin D, any other medication, or food/beverage 
(except water) together with study drug or during the 
predose or postdose fasting period.
Participants
All patients from PRIOR were included in this analysis. 
PRIOR recruited women who had discontinued previous 
daily or weekly BP treatment at least three months earlier 
due to GI intolerance.
The present analysis included data from a subset of 
patients from the CURRENT study with GI symptoms 
on weekly BPs at enrollment, who then received monthly 
oral ibandronate 150 mg for six months.28 CURRENT 
included women currently receiving weekly BP treat-
ment who switched to monthly ibandronate. Patients with 
contraindications to calcium or vitamin D; inability to stay 
in an upright position for 60 minutes; history of hyper-
calcemia, renal disease, or liver disease; and a history of 
major upper GI disease (significant upper GI bleeding 
within the last year requiring hospitalization or transfusion; 
recurrent peptic ulcer disease documented by radiographic 
or endoscopic means; dyspepsia or gastroesophageal reflux 
uncontrolled by medication; abnormalities of the esophagus 
that delay esophageal emptying, such as stricture, achalasia, 
or dysmotility; and active gastric/duodenal ulcers) were 
excluded from CURRENT.
Patients who reported GI symptoms at baseline in 
CURRENT were identified for the present subanalysis 
based on their responses to the OPSAT-Q™. Patients with 
an OPSAT-Q™ score of 1 to 4 on 1 or more of the following 
questions: 11, 12, 14, 15 were included in the analysis 
(Figure 1).
Assessments
GI symptoms were assessed with questions selected from 
the OPSAT-Q™ in both trials (Figure 1). Scores from the 
selected OPSAT-Q™ questions were compared at screening 
(previous treatment) and months 1, 4, 7, and 10 in PRIOR, and 
at screening and month 6 in CURRENT. A five-point scale was 
used for each question. In PRIOR, a score of 1 for questions 
11 to 13 indicated an answer of “extremely bothered,” while a 
score of 5 specified that the patient was “not bothered at all.” 
Similarly, for questions 14 to 16, which dealt with the frequency 
of GI symptoms, a score of 1 was awarded for an answer 
of “more than 3 days” and 5 for an answer of “0 days.”
statistical analysis
The proportions of patients who reported improved, worsened, 
or unchanged GI symptoms on the OPSAT-Q™ questions at Clinical Interventions in Aging 2009:4 359
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the end of the study compared with screening were analyzed 
for both studies. Additionally, for PRIOR, OPSAT-Q™ 
responses were transformed into an overall GI tolerance score 
on a scale of 0 to 100, with a higher GI tolerability score 
indicating less frequent and/or less severe symptoms:
Results
Patient demographics and baseline 
characteristics
Demographic and baseline characteristics are summarized in 
Table 1. In total, 147 participants in PRIOR (27.1%) chose oral 
and 396 (72.9%) chose IV ibandronate. The participants’ mean 
age was 65.7 years in the oral treatment group and 66.2 years 
in the IV treatment group. Most participants had a diagnosis of 
osteoporosis (84 oral [57.1%], 286 IV [72.2%]); the rest of the 
study population had a diagnosis of osteopenia. Detailed demo-
graphic and baseline data have been presented elsewhere.25
Questions regarding severity of side effects*
Screening: How bothered are you by the following side effects that you may or may not 
experience  after  taking  your  previous  osteoporosis/osteopenia  medication?  If  you  have 
never experienced the side effect from the medication, please answer "Not at All Bothered."
Treatment Phase: How bothered are you by the following side effects that you may or may 
not experience after taking your current osteoporosis/osteopenia medication? If you have 
never experienced the side effect from the medication, please answer "Not at All Bothered."
PRIOR  CURRENT
11. Heartburn or acid reflux
12. Stomach upset other than heartburn
or acid reflux  (such as diarrhea, nausea,
vomiting, or stomach pain)
13. Any other side effects  you think are related
to your osteoporosis medication
Scale of "Not at all bothered", "Slightly bothered",
"Moderately bothered", "Quite a bit bothered",
"Extremely bothered"
Questions regarding frequency of side effects*
Screening: When on medication, approximately how many days per month did you experi-
ence the following side effects associated with your osteoporosis/osteopenia medication?
Treatment Phase: When on medication during the last 4 weeks, approximately how many 
days per month did you experience the following side effects associated with your 
osteoporosis/osteopenia medication?
PRIOR  CURRENT
14. Heartburn or acid reflux
15. Stomach upset other than heartburn
or acid reflux  (such as diarrhea, nausea,
vomiting, or stomach pain)
X
X X
X
– X
16. Any other side effects  you think are related
to your osteoporosis medication
Scale of "0 days", "1 day", "2 days", "3 days", "More than 3 days"
X
X
X −
X
X
Figure 1 Questions from the Osteoporosis Patient satisfaction Questionnaire™ (OPsAT-Q™) used to assess gastrointestinal symptoms in the PRIOR and CURRenT studies.
Notes: *Question numbers refer to the numbers in the complete OPsAT-Q™. © for the OPsAT-Q Roche Laboratories, Inc.    All Rights Reserved.
Within-group comparisons of GI tolerance scores in PRIOR 
were conducted using t-tests.
GItolerancescore
=
(Sumof actualscores Sumof lowest possiblesco − r res) 100
Sumof highest possiblescores
×Clinical Interventions in Aging 2009:4 360
Derman et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
In the CURRENT study, participants with GI symptoms 
at baseline were identified by a score of 1 to 4 on at least 
1 of the relevant OPSAT-Q™ questions. Overall 438, 339, 
231, and 159 women had a score of at least 1 on questions 
11, 12, 14, and/or 15, respectively. Detailed demographic and 
baseline data have been presented elsewhere.28
gI symptoms
In PRIOR, over 75% of participants in both the oral and IV 
groups reported 10% increase in GI tolerability scores 
at all post-screening evaluations compared with screening 
(oral range: 77.9%–85.5%; IV range: 83.7%–85.8%). The 
majority of patients reported improvement in symptom 
severity scores (questions 11–13) from baseline at all 
post-screening assessments, with 70% of participants 
indicating improvement at month 1. The pattern of improve-
ment in GI symptom frequency scores (questions 14–16) 
was similar to that in GI symptom severity scores. Over 
90% of participants in each group reported improvements on 
Table 1 Baseline and demographic characteristics
Characteristic PRIOR:   All 
participants 
(N = 543)
CURRENT: 
participants 
who reported 
GI symptoms 
during screening 
(n = 89)
Race
    White/Caucasian 508 (94) 82 (92)
  Black 15 (3) 4 (4)
  Other 20 (4) 3 (3)
Age, years
  n 543
  Mean ± sD 66.0 ± 10.55 63.6 ± 10.62
  Range 37–99 41–86
Weight, kg
  n 540
  Mean ± sD 65.0 ± 12.32
  Range 37–125
Height, cm
  n 541
  Mean ± sD 159.8 ± 6.88
  Range 130–182
BMI, kg/m2
  n 539
  Mean ± sD 25.5 ± 4.88 25.8 ± 5.36
  Range 14–49 17.8–42.1
Highest level of education
  elementary school 11 (2)
  some high school 35 (6)
  high school graduate/geD 141 (26)
  some college 170 (31)
  College graduate 130 (24)
  Postgraduate degree 56 (10)
Current occupation
  not working 370 (68)
    Working 173 (32)
Major risk factors for 
osteoporosis
    Low body weight (58 kg) 184 (33.9) 26 (29.2)
    history of fractures as an adult 174 (32.0) 32 (36.0)
    history of fragility fracture  
in 1st degree relative
126 (23.2) 15 (16.9)
  Current smoker 60 (11.0) 11 (12.4)
    Use of oral corticosteroid  
therapy for 3 months
53 (9.8) 5 (5.6)
  none of above 168 (30.9) 24 (27.0)
Primary diagnosis
  Osteoporosis 370 (68.1) 63 (70.8)
  Osteopenia 173 (31.9) 26 (29.2)
(Continued)
Table 1 (Continued)
Characteristic PRIOR:   All 
participants 
(N = 543)
CURRENT: 
participants 
who reported 
GI symptoms 
during screening 
(n = 89)
Months since diagnosis, 
mean ± SD
  Osteoporosis – 57.1 ± 50.24 
(n = 63)
  Osteopenia – 36.4 ± 23.63 
(n = 26)
Months since stopping 
alendronate or risedronate
  Mean ± sD 23.4 ± 25.82 –
  Range 1.4–144.0 –
GI tolerance score
  0 to 25 65 (12.0)
  25 to 50 168 (31.1)
  50 to 75 207 (38.3)
  75 to 100 100 (18.5)
    Total reported 540
Taking osteoporosis/osteopenia 
medication
0 89 (100)
Years of taking osteoporosis/
osteopenia medication, 
mean ± sD (n = 87)
– 2.4 ± 1.9
Note: Data presented are number (%) unless otherwise noted.
Abbreviations: geD, general education development; gI, gastrointestinal; 
sD, standard deviation.Clinical Interventions in Aging 2009:4 361
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each question at month 10 (Figure 2). Mean GI tolerability 
scores were significantly higher at month 1 compared with 
screening for both the oral and IV treatment groups (oral: 79.3 
versus 54.1; IV: 84.4 versus 51.0, respectively; p  0.001 
for both groups). The scores continued to increase for both 
groups at months 4, 7, and 10 and remained significantly 
higher compared with screening scores at all assessment 
points (p  0.001 for both groups).
A similar result was observed in the CURRENT study, 
where the majority of women with GI symptoms on their 
current weekly BP indicated improvements in degree of 
bother and frequency of GI symptoms six months after 
switching to monthly oral ibandronate (Figure 3). Over 60% 
of patients reported improvements in heartburn or acid reflux 
(bother: 62.6%; frequency: 66.4%) and over 70% indicated 
an improvement in stomach upset other than heartburn or 
acid reflux (bother: 72.7%; frequency: 74.8%) at month 6.
Discussion
This analysis aimed to assess whether extended ibandronate 
dosing was associated with improved GI tolerability in patients 
who had previously experienced GI irritation with daily or 
weekly BP use. In both the PRIOR and CURRENT trials, 
women reported improvement in the GI symptoms they had 
encountered in previous treatment with daily or weekly BPs. 
The GI tolerability scores improved significantly for patients 
in the PRIOR study, and patients in both studies reported 
improvements in symptom severity and frequency scores.
Evidence from previous research on the occurrence of 
GI symptoms associated with oral BP treatment has been 
mixed. RCTs have generally reported a rate of GI adverse 
events similar to placebo with all BPs.4,5,18–21 However, after 
the introduction of daily alendronate, an increase in GI 
symptoms was reported29,30 and results from later studies 
further supported the link between BP treatment and GI 
events.12,22 BPs have been shown to induce ulceration and 
necrosis in gastric mucosa.15,29 Although the mechanism 
of BP-induced GI irritation is not well understood, a study 
in human colon tumor cells suggests that BPs induce 
apoptosis and/or inhibition of proliferation of epithelial 
cells.31 Another ex vivo study showed evidence of neutrophil 
accumulation and epithelial damage in the gastric mucosa 
of rats on contact with high concentrations of alendronate 
or pamidronate.32
In order to minimize contact of BPs with gastric mucosa, 
the current administration recommendations for orally 
administered BPs were developed. The dosing instructions 
for weekly BPs state that the drug should be administered 
with a glass of water 30 minutes before the first food or 
beverage of the day and the patient should not lie down 
within 30 minutes after dosing.16 However, despite the 
changes in the method of administration, recent data suggest 
A) Oral ibandronate
0 20 40 60 80 100
Other side effects:
frequency (n = 33)
Other side effects:
bother (n = 33)
Stomach upset:
frequency (n = 78)
Stomach upset:
bother (n = 78)
Heartburn/acid
reflux: frequency
(n = 90)
Heartburn/acid
reflux: bother
(n = 92)
Improved
Worsened
No change
Patients (%)
Question 15
Question 12
Question 14
Question 11
Question 13
Question 16
0 20 40 60 80 100
Other side effects:
frequency (n = 102)
Other side effects:
bother (n = 106)
Stomach upset:
frequency (n = 222)
Stomach upset:
bother (n = 225)
Heartburn/acid
reflux: frequency
(n = 266)
Heartburn/acid
reflux: bother
(n = 271)
Patients (%)
Question 15
Question 12
Question 14
Question 11
Question 13
Question 16
B) Intravenous ibandronate Improved
Worsened
No change
Figure 2 PRIOR: Change in self-reported gastrointestinal symptoms for patients with gastrointestinal symptoms at baseline (score of 1–4 on at least 1 of Osteoporosis Patient 
satisfaction Questionnaire™ questions 11, 12, 13, 14, 15, 16) at Month 10.Clinical Interventions in Aging 2009:4 362
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that GI symptoms still account for a high proportion of 
discontinuations in clinical practice.12,13 IV administration, 
while requiring an injection, avoids contact of the BP with 
the gastric mucosa.
In a recent database analysis, fewer severe GI events 
occurred in patients receiving monthly oral ibandronate 
compared with weekly BPs, although the incidence of these 
events was low for all treatments.17 In addition, 100% of 
patients receiving weekly BPs who had an event discon-
tinued treatment. In contrast, only 44% of those receiving 
monthly ibandronate who experienced an event discontinued. 
A separate analysis has suggested that GI event rates may 
be lower with risedronate than with alendronate.33
There are several possible reasons for the varying 
findings for BP-related GI events. RCTs employ stringent 
inclusion and exclusion criteria that exclude patients in 
poorer health, so the rate of GI symptoms may be lower in 
RCT populations than in the general population of patients 
receiving BPs. GI symptoms troublesome enough to prompt 
discontinuation may not be so severe that patients in an 
RCT report them. Furthermore, patients in normal clinical 
practice may follow administration guidelines less closely 
than those in an RCT, increasing the risk of GI symptoms. 
Most RCTs report GI events as adverse events.4,5,18 The 
questionnaires used in PRIOR and CURRENT, with their 
specific GI-focused questions, may be a more sensitive 
tool for identifying GI symptoms than adverse event 
reporting.
PRIOR and CURRENT included distinct populations, 
both expected to be at risk of experiencing GI symptoms. 
Women in the PRIOR study had discontinued previous BP 
therapy due to GI symptoms, and women in the CURRENT 
subanalysis had experienced GI symptoms on their current 
BP before switching to oral ibandronate. Improvements 
reported in GI symptoms in this at-risk group may have 
clinical implications for other patients who have discontinued 
BPs due to GI symptoms or who are experiencing 
GI irritation with current BP treatment. Initiating monthly 
oral or quarterly IV ibandronate may be associated with 
improvement in self-reported GI symptoms. Since occurrence 
0 20 40 60 80 100
Question 11
Heartburn/acid
reflux: bother
(n = 438)  
Question 14
Heartburn/acid
reflux: frequency
(n = 339)
Question 12
Stomach upset:
bother (n = 231)
Question 15
Stomach upset:
frequency
(n = 159)
Improved 
Worsened 
No change 
Missing 
Patients (%)
274/438 (63%)
168/231 (73%)
119/159 (75%)
225/339 (66%)
Figure 3 CURRenT: Change in self-reported gastrointestinal symptoms for patients with gastrointestinal symptoms at baseline (score of 1–4 on at least 1 of Osteoporosis 
Patient satisfaction Questionnaire™ questions 11, 12, 14, 15) at Month 6.Clinical Interventions in Aging 2009:4 363
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of GI events is associated with poor adherence to BP therapy, 
this may help these patients to persist with BP treatment, 
and therefore be more likely to realize the benefits of BPs 
in terms of fracture risk reduction.
The benefits of oral alendronate, risedronate, and 
ibandronate on fracture risk reduction for patients with 
postmenopausal osteoporosis were established in studies 
of daily formulations of each product. Subsequent studies 
compared the efficacy of longer dosing interval regimens 
of these products with the corresponding daily formula-
tions in terms of BMD increase, which is associated with 
reduced fracture risk. Studies of daily alendronate and 
risedronate demonstrated that these regimens significantly 
reduce the risk of vertebral and nonvertebral or hip fractures 
compared with placebo.5,18,20,34,35 Ibandronate 2.5 mg daily 
was shown to significantly reduce the rate of vertebral 
fractures compared with placebo,4 and to significantly 
reduce the rate of nonvertebral fractures in a high-risk 
population.36 Weekly alendronate, and both weekly and 
monthly risedronate provide similar cumulative doses 
to the corresponding daily regimens. For these products, 
the longer dosing interval regimens produced similar 
BMD increases from baseline to the corresponding daily 
formulations.37–39 Monthly ibandronate 150 mg provides 
a higher cumulative dose to ibandronate 2.5 mg daily, 
and was shown to provide a significantly larger BMD 
increase.40 Recent pooled analyses of individual patient 
data from ibandronate studies have suggested that higher 
dose regimens, including monthly oral ibandronate 150 mg 
reduce the risk of nonvertebral fractures.41,42 In a recent 
database analysis, monthly ibandronate treatment was 
associated with a similar risk of nonvertebral fracture as 
weekly BPs.43
A few limitations of  this investigation should also be noted. 
The two studies included no comparators. It is not certain 
what outcomes would have resulted from rechallenge with 
a weekly BP (PRIOR) or continued treatment (CURRENT). 
CURRENT and PRIOR were open-label studies, so the 
possibility of bias being introduced by the inclusion of 
motivated patients cannot be excluded. The participants in 
PRIOR had a wide variation in the time between ending their 
previous treatment and entering the study. The baseline GI 
tolerance score reflected patients’ recollection of GI symp-
toms associated with previous treatment. The possibility 
that patients answered the questionnaire differently when 
reporting symptoms associated with ongoing ibandronate 
treatment in the study cannot be excluded. The CURRENT 
subanalysis was a post hoc analysis.
The results from the PRIOR and CURRENT studies 
suggest that women with GI tolerability issues on a daily or 
weekly BP regimen may experience improved symptoms with 
the less frequent dosing regimens of monthly oral or quarterly 
IV ibandronate. The improved GI tolerability associated with 
extended ibandronate dosing may help to improve adherence 
to BP therapy, thus, reducing fracture risk in women with 
postmenopausal osteoporosis.
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